UTMB study shows common antibody therapy has anti-SARS-CoV-2 Antibodies

Scienmag

GALVESTON, Texas – Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS–COV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community. Latest News Antibodies antibody antiSARSCoV2 common shows study therapy UTMB

How a COVID-19 infection spurs antibodies against common colds

Scienmag

LA JOLLA, CA—Getting sick with a common cold doesn’t make you immune to COVID-19, but a COVID-19 infection might, at least temporarily, boost the number of antibodies you have against common cold-causing coronaviruses and the SARS-CoV-1 and MERS-CoV viruses, all of which are closely related.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scripps Research scientists explain what makes COVID-19 antibody “J08” so potent

Scienmag

LA JOLLA, CA—Last year, scientists at Scripps Research and Toscana Life Sciences studied the blood of 14 COVID-19 survivors to find the most potent antibodies against the SARS-CoV-2 virus. Medicine & Health antibody COVID19 explain J08 potent research scientists Scripps

Antibody shows promise for developing hantavirus treatment

Scienmag

An international research team discovered the first human antibody to effectively neutralize two types of hantaviruses in animal models, according to a study published online Mar. Biology antibody developing hantavirus promise shows treatment

Scientists identify antibodies that can neutralize omicron

Scienmag

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

Regeneron antibody cuts risk of COVID-19 death in UK study

Bio Pharma Dive

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients

Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention

Bio Pharma Dive

The expanded authorization comes amid surging demand for antibody treatments, particularly in states with lower rates of coronavirus vaccination

Who would get Regeneron's COVID-19 antibody treatment?

Bio Pharma Dive

Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

New COVID-19 nasal spray outperforms current antibody treatments in mice

Scienmag

Medicine & Health antibody COVID19 current mice nasal outperforms spray treatmentsA new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St.

Antibody with engineered peptide targets bone metastasis

Scienmag

Cancer antibody bone Engineered metastasis peptide targetsHOUSTON – (Jan. 24, 2022) – A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.

Eli Lilly wins FDA emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact

FDA clears Lilly's COVID-19 antibody cocktail for emergency use

Bio Pharma Dive

In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death

Antibody function antibody dependent cellular cytotoxicity (ADCC) may help prevent the transmission of HIV from mother to child during breastfeeding

Scienmag

BOSTON – According to new research from Boston Medical Center, the antibody function known as antibody dependent cellular cytotoxicity (ADCC) and the ADCC sensitivity of HIV strains may influence the transmission of HIV from mother to child during breastfeeding. Latest News ADCC antibody breastfeeding cellular child cytotoxicity dependent function HIV mother prevent transmission

Behind the made-in-Canada approach to tracking COVID-19 antibodies

Scienmag

Technology and Engineering Antibodies approach COVID19 madeinCanada trackingWith every quiet pass of the robotic arm in a research lab at the Lunenfeld-Tanenbaum Research Institute (LTRI) in downtown Toronto, more questions about COVID-19 are being answered.

Study suggests severe obesity blunts antibody response to COVID-19 vaccines

Scienmag

Latest News antibody blunts COVID19 obesity response severe study suggests VaccinesNew research being presented at this year’s European Congress on Obesity (ECO) in Maastricht, Netherlands (4-7 May), suggests that adults (aged 18 or older) with severe obesity generate a significantly weaker immune response to COVID-19 vaccination compared to those with normal weight. The study is by Professor Volkan Demirhan Yumuk from Istanbul University in Turkey […].

US buys up supply of new Lilly antibody meant to work versus omicron

Bio Pharma Dive

Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday

Sanofi pays IGM $150M, continuing search for better antibody drugs

Bio Pharma Dive

The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines

Mayo Clinic researchers develop new antibody test to diagnose MS

Scienmag

Mayo Clinic researchers have validated a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. An antibody typically consists of two immunoglobulin heavy chains and […]. Latest News antibody Clinic develop diagnose Mayo researchers testROCHESTER, Minn. Nearly 1 million people in the U.S. are affected by MS, according to the National Multiple Sclerosis Society.

Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody

Bio Pharma Dive

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.

AstraZeneca antibody cleared by FDA for preventive use against COVID-19

Bio Pharma Dive

Evusheld, a combination of two antibodies, is meant to be long-acting, proving protective against disease through six months in clinical testing

Model shows how antibodies navigate pathogen surfaces like a child at play

Scienmag

A new study shows how antibodies select the antigens that they bind to, as they navigate the surface of pathogens like coronaviruses. Medicine & Health Antibodies child model navigate pathogen play shows surfaces

Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

Bio Pharma Dive

The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech

A startup raises $336M to make a better antibody drug for COVID-19

Bio Pharma Dive

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests

J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies

Bio Pharma Dive

Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors

Unexpected antibody type found in people with malaria infections

Scienmag

However, in a newly published study, researchers at the University of Maryland School of Medicine (UMSOM) have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as […].

US pauses distribution of Regeneron, Lilly antibodies over omicron concerns

Bio Pharma Dive

The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread

FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

US stops rollout of Lilly's first COVID-19 antibody over variant concerns

Bio Pharma Dive

Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials

Infection plus vaccination yields better antibodies against COVID-19 variants

Scienmag

Antibodies against the SARS-CoV-2 spike protein produced by the immune system can help identify and fend off future infections, but not all antibodies are the same. Latest News Antibodies COVID19 infection vaccination variants yieldsWashington, D.C. People who either recovered from COVID-19 early in the pandemic or received a current vaccine may not be able to fend off new and emerging variants. […].

F.D.A. Clears Monoclonal Antibody Drug From Eli Lilly

NY Times

The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness. Eli Lilly and Company Antibodies Food and Drug Administration Coronavirus Omicron Variant Drugs (Pharmaceuticals) Coronavirus (2019-nCoV

Merck to pay almost $3B for VelosBio, broadening antibody cancer drug push

Bio Pharma Dive

Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround

NK cells combined with bispecific antibody showed strong response for patients with lymphoma

Scienmag

Abstract: CT003 Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma. Latest News antibody bispecific cells combined lymphoma Patients response showed strong

Antibody Drug to Protect the Vulnerable From Covid Goes Unused

NY Times

Shortages AstraZeneca PLC Immune System Antibodies Coronavirus (2019-nCoV) Chronic Condition (Health) Drugs (Pharmaceuticals) Transplants United States Politics and Government

Current anti-COVID pills work well against omicron, but antibody drugs are less effective

Scienmag

Biology antibody antiCOVID current Drugs effective Omicron pills workMADISON, Wis. — The drugs behind the new pills to treat COVID-19 remain very effective against the omicron variant of the virus in lab tests, according to a new study. Credit: University of Wisconsin-Madison MADISON, Wis. —

Longer interval between COVID-19 vaccines generates up to nine times as many antibodies

Scienmag

Latest News Antibodies COVID19 generates interval longer times Vaccines**Note: this is a press release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022, Lisbon, 23-26 April). Please credit the conference if you use this story** New research to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, (23-26 April), has shown that […].

COVID-19 neutralising antibody tests – an integrated approach

Pharma Phorum

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies.

Biologists isolated the coronavirus nucleoprotein in its pure form to improve the accuracy and sensitivity of the antibody tests

Scienmag

COVID-19 patients usually develop antibodies (immunity proteins that are specifically […]. Technology and Engineering accuracy antibody biologists coronavirus form improve isolated nucleoprotein pure sensitivity tests

RNA 83

Common coronavirus infections don’t generate effective antibodies against SARS-CoV-2

Scienmag

Now, researchers reporting in ACS Infectious Diseases have shown that infections with two different HCoVs don’t generate antibodies that effectively cross-react with SARS-CoV-2. Latest News Antibodies common coronavirus dont effective generate infections SARSCoV2Although SARS-CoV-2 has taken the world by storm, it’s not the only coronavirus that can infect humans. But unlike SARS-CoV-2, common human coronaviruses (HCoVs) generally cause only mild disease.

JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business

Bio Pharma Dive

Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.

F.D.A. Authorizes Another Antibody Treatment

NY Times

internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.